# Study Guide: Transcutaneous and Percutaneous Ablation for Breast Tumors This study guide provides a comprehensive overview of the current data, indications, and clinical recommendations for the use of transcutaneous and percutaneous ablation in treating benign and malignant breast tumors, based on the 2026 resource guide from The American Society of Breast Surgeons (ASBrS). --- ## Key Concepts and Clinical Data ### 1. Treatment of Benign Tumors (Fibroadenomas) While fibroadenomas have low malignant potential and do not strictly require treatment on an oncologic basis, patients may seek removal due to discomfort or preference. * **Traditional Treatment:** Open surgical excision remains effective but can cause scarring, breast contour changes, and mammographic distortion. * **Percutaneous Methods (FDA Approved):** These methods offer minimal scarring and no visible contour changes. * **Cryoablation:** In studies (Golatta et al.), 93% of tumors were neither palpable nor visible on ultrasound at one year. Cosmesis was rated good or excellent by 97% of patients. * **Ultrasound-Guided Percutaneous Excision (Vacuum-Assisted):** Large-scale studies (Li et al.) showed a local recurrence rate of only 1.9%, typically associated with larger lesions or procedure-related hematomas. 98% of patients reported satisfaction with the cosmetic appearance. * **Transcutaneous Methods (Investigational):** * **Focused Microwave Ablation (MWA):** Shows promising volume reduction but requires larger clinical trials. * **Focused Ultrasound Ablation (FUA):** Effective outside the U.S. and Europe; currently under investigation in the U.S. and not yet FDA-approved. ### 2. Treatment of Malignant Tumors (Breast Cancer) The use of ablation for malignancy is typically reserved for early-stage, low-risk cases or patients who are poor surgical candidates. * **The ICE3 Trial:** A prospective study evaluating cryoablation in women $\geq$60 years with low-risk invasive ductal carcinoma (IDC) $\leq$1.5cm. * **Results:** At five-year follow-up, the Ipsilateral Breast Tumor Recurrence (IBTR) rate was 4.3%, and breast cancer survival was 96.7%. * **FDA Approval (October 2025):** Granted Class II approval for cryoablation in patients $\geq$70 years with biologically low-risk IDC $\leq$1.5cm. ### 3. Comparison of Primary Ablation Modalities | Modality | Type | Status for Fibroadenoma | Status for Malignancy | | :--- | :--- | :--- | :--- | | **Cryoablation** | Percutaneous | FDA Approved | FDA Approved (Age $\geq$70, $\leq$1.5cm) | | **Vacuum-Assisted Excision** | Percutaneous | FDA Approved | Investigational | | **Microwave Ablation (MWA)** | Transcutaneous | Investigational | Investigational | | **Focused Ultrasound (FUA)** | Transcutaneous | Investigational (US) | Investigational | --- ## Clinical Indications and Requirements ### Selection Criteria for Cryoablation The following table outlines the requirements for both benign and malignant cases: | Requirement | Benign (Fibroadenoma) | Malignant (Invasive Ductal Carcinoma) | | :--- | :--- | :--- | | **Imaging** | Easily visible on ultrasound | Easily visible on ultrasound | | **Diagnosis** | Histologically confirmed core biopsy | Grade 1-2 IDC; HR+; HER2-; Ki67 <15% | | **Size Limit** | < 4 cm | $\leq$ 1.5 cm | | **Patient Age** | N/A | $\geq$ 70 years old | | **Nodal Status** | N/A | Clinically node-negative (ultrasound confirmed) | ### Contraindications for Malignancy Ablation Ablation is **not** recommended for patients with: * Lobular carcinoma. * Extensive intraductal component (EIC) $\geq$25%. * Multifocal or multicentric disease. * Multifocal calcifications on mammogram. * Evidence of lymphovascular invasion. * Known coagulopathy or thrombocytopenia. * Prior surgical biopsy of the target lesion. * History of neoadjuvant therapy. --- ## Short-Answer Practice Questions 1. **What are the primary advantages of percutaneous or transcutaneous treatment over traditional open surgical excision for fibroadenomas?** * *Answer:* Minimal to no visible contour or aesthetic changes, minimal scarring, and the avoidance of distortion on future mammograms. 2. **According to the ICE3 trial, what was the five-year Ipsilateral Breast Tumor Recurrence (IBTR) rate for patients undergoing cryoablation?** * *Answer:* 4.3%. 3. **What safety measures can be taken during cryoablation to protect the skin or chest wall from thermal injury?** * *Answer:* Saline hydrodisplacement and/or the use of warm packs. 4. **Why is histological confirmation via core biopsy required before treating a suspected fibroadenoma with ablation?** * *Answer:* To ensure the diagnosis is concordant with imaging and to rule out malignancy before the lesion is ablated. 5. **What is the "learning curve" consideration for surgeons adopting cryoablation?** * *Answer:* Surgeons must have considerable ultrasound experience and technical competency in percutaneous techniques, as precise needle placement is critical to success. --- ## Essay Prompts for Deeper Exploration 1. **The Shift Toward De-escalation:** Discuss how the FDA approval of cryoablation for low-risk breast cancer in patients $\geq$70 reflects a broader trend in surgical oncology. What are the potential benefits and risks of replacing surgical excision with ablation in this specific demographic? 2. **Multidisciplinary Management:** The ASBrS guidelines emphasize that cryoablation must be part of a "comprehensive treatment plan." Explain the roles of the surgeon, radiologist, and oncologist in managing a patient who chooses ablation over surgery, specifically regarding axillary management and systemic therapy. 3. **Investigational vs. Standard of Care:** Compare Focused Ultrasound Ablation (FUA) and Microwave Ablation (MWA) with Cryoablation. Why has cryoablation reached FDA approval for certain indications while the others remain investigational in the United States? --- ## Glossary of Important Terms * **Ablation:** The destruction of tissue, typically via extreme heat or cold, without physical surgical removal. * **Cryoablation:** A percutaneous technique that uses extreme cold to destroy tumor tissue. * **Concordant:** When the results of different tests (e.g., physical exam, imaging, and pathology) all support the same diagnosis. * **Extensive Intraductal Component (EIC):** A condition where 25% or more of a core biopsy specimen contains intraductal neoplasia; a contraindication for cryoablation in malignancy. * **Fibroadenoma:** A common, benign (non-cancerous) breast tumor. * **Invasive Ductal Carcinoma (IDC):** The most common type of breast cancer; specifically targeted in the ICE3 cryoablation trial. * **Ipsilateral Breast Tumor Recurrence (IBTR):** The return of cancer in the same breast where the original tumor was treated. * **Percutaneous:** A procedure performed through a small needle-sized opening in the skin. * **Saline Hydrodisplacement:** A technique used to create space between a tumor and the skin or chest wall by injecting saline to prevent thermal damage during ablation. * **Transcutaneous:** A non-invasive treatment method that acts through the skin without an incision or puncture (e.g., focused ultrasound).